Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

doi:10.1200/PO.24.00240

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

JCO precision oncology - 1 Dec 2024

Di Federico Alessandro, Angelicola Stefania, Frascino Mariateresa, Siracusa Irene, Bisanti Beatrice, Ruzzi Francesca, Semprini Maria Sofia, De Jonge Hugo, De Giglio Andrea, Sperandi Francesca, Brocchi Stefano, Melotti Barbara, Giunchi Francesca, Gruppioni Elisa, Altimari Annalisa, Lollini Pier-Luigi, Ardizzoni Andrea, Palladini Arianna, Gelsomino Francesco

Abstract excerpt

PURPOSE: Patients with tumors harboring BRAF class 3 mutations lack targeted therapies. These mutations are characterized by low/absent BRAF kinase domain activation and are believed to amplify already active RAS signaling, potentially triggered by receptor tyrosine kinases like EGFR. MATERIALS AND METHODS: Two patients with BRAF class 3-mutated metastatic non-small-cell lung cancer (NSCLC) were treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39637338
DOI: 10.1200/PO.24.00240
PMCID: PMC11661570

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.PMID 39637338Read ↗

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Semantic proximity Read ↗

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerSemantic proximity Read ↗

HER-3 Expression and MEK Activation in Non-small Cell Lung CancerSemantic proximity Read ↗

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

Pathways and targeting avenues of BRAF in non-small cell lung cancer.Semantic proximity Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.